Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10803663
Filing Date		2004-03-18
First Named Inventor DeW		itt, Jr. et al.
Art Unit		2122
Examiner Name Dam,		, Tuan Quang
Attorney Docket Numb	er	AUS920030548US1

				U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines wh Relevant Passages or Re Figures Appear			
	1	6973417	B1	2005-12-06	Maxwell et al	L			
	2	6721875	B1	2004-04-13	McCormick e	tal.			
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information pl	lease click the	Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite	Publication Number	Kind Code <sup>1</sup>	Publication	Name of Pat	tentee or Applicant		Columns, Lines wh ant Passages or Re	
	1			Date	or ated Doa	ument		s Appear	
If you wis	Ċ	dd additional U.S. Publ	ished Ap	plication citation	n information	please click the Ad	Figure	n. Add	
If you wis	Ċ	dd additional U.S. Publ	ished Ap		n information	please click the Ad	Figure d button	n. Add	
Examiner	h to a	dd additional U.S. Publ Foreign Document Number <sup>3</sup>	ished Ap	plication citation	n information	please click the Ad	Figure d button	n. Add	76
If you wis Examiner Initial*	h to a	Foreign Document	ished Ap	plication citation	n information	please click the Add	Figure d button	Add  Remove Pages, Columns, Lin where Relevant Passages or Releva	76

	Application Number		10803663	
INFORMATION DIGGS COURT	Filing Date		2004-03-18	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	DeW	itt, Jr. et al.	
(Not for submission under 37 CFR 1.99)	Art Unit		2122	
(Not to submission and or or trissy	Examiner Name	Dam,	, Tuan Quang	
	Attorney Docket Numb	er	AUS920030548US1	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

## Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Knd Codes of USPTO Patent Documents at year LISPTO, GDU or MPEP 901.04. <sup>2</sup> Either office that issued the document, by the bo-later code (WIPO Standard ST3.) <sup>3</sup> Sor Juapanes patent concuments, by managed the common state of the Empower managed code the search counterful. <sup>4</sup> Knill of document by the appropriate symbols as adicated on the document under WIPO Standard ST.16 if possible. <sup>3</sup> Applicant is to place a check mark here if English Imaguage translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10803663	
Filing Date		2004-03-18	
First Named Inventor	DeWitt, Jr. et al.		
Art Unit		2122	
Examiner Name	Dam,	Tuan Quang	
Attorney Docket Numb	er	AUS920030548US1	

### CERTIFICATION STATEMENT

Please see 3	7 CFR 1	.97 and	1.98 to make th	e appropriate selection(s):
--------------	---------	---------	-----------------	-----------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c) The 1.57(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c) the statement of the filing of the information disclosure

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gerald H. Glanzman/	Date (YYYY-MM-DD)	2006-08-21					
Name/Print	Geraid H. Glanzman	Registration Number	25035					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.511-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.32.311-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issuand patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.